title: Can gadopentetate dimeglumine be safely administered more rapidly than the FDA-approved injection rate for liver imaging?
authors: Masoud
authors: M
authors: Shiehmorteza
authors: Robert F
authors: RF
authors: Hanna
authors: Michael S
authors: MS
authors: Middleton
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D017277:Drug Approval; D005260:Female; D019786:Gadolinium DTPA / Q000008:administration & dosage* / Q000009:adverse effects*; D006261:Headache / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007275:Injections, Intravenous; D008099:Liver / Q000473:pathology*; D008107:Liver Diseases / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000453:epidemiology; D039781:PubMed; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003287:Contrast Media; D019786:Gadolinium DTPA